Summary
41 / 100 · Bulios Score
What speaks for it
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- You pay 44.7 USD for 1 USD of yearly profit, a lot for its sector.
- Repaying its net debt would take 4.0 years of operating profit.
- Out of every 100 USD of revenue, only 2.3 USD is left as net profit.
- It earns only 4.0 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedToday you pay 44.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 9.9%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 75 USD
- Sales and administration 19 USD
- Taxes and other 3.8 USD
- Net profit 2.3 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 2.3 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 15
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $44.33 is 26% above today's price. 88% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.